阿托伐他汀联合曲美他嗪治疗冠心病的临床效果分析

Clinical Effect Analysis of Atorvastatin Combined with Trimetazidine in the Treatment of Coronary Heart Disease

目的:探究阿托伐他汀联合曲美他嗪治疗冠心病的临床效果。方法:选取2019年1月—2022年1月陇南市第一人民医院收治的冠心病患者86例作为观察对象,通过随机抽签法分为参照组和观察组,各43例。参照组给予曲美他嗪治疗,观察组在对照组基础上给予阿托伐他汀治疗。比较两组血脂指标[总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)]、心功能指标、不良反应发生率、治疗效果。结果:治疗前,两组TC、TG、HDL-C、LDL-C水平比较,差异无统计学意义(P>0.05);治疗后,两组TC、TG、LDL-C水平低于治疗前,HDL-C水平高于治疗前,观察组TC、TG、LDL-C水平低于参照组,HDL-C水平高于参照组,差异有统计学意义(P<0.05)。治疗前,两组左室后壁收缩末期厚度、室间隔厚度、左室射血分数、左室舒张末期内径、左室收缩末期内径比较,差异无统计学意义(P>0.05);治疗后,两组左室后壁收缩末期厚度、室间隔厚度、左室舒张末期内径、左室收缩末期内径低于治疗前,左室射血分数高于治疗前,观察组优于参照组,差异有统计学意义(P<0.05)。观察组不良反应发生率低于参照组,差异有统计学意义(P=0.0259)。观察组治疗总有效率高于参照组,差异有统计学意义(P=0.0486)。结论:应用阿托伐他汀联合曲美他嗪治疗冠心病,能够改善患者的血脂水平,促进心功能恢复,减少不良反应,效果显著。

Objective:To explore the clinical effect of atorvastatin combined with trimetazidine in the treatment of coronary heart disease.Methods:A total of eighty-six patients with coronary heart disease admitted to the Longnan First People's Hospital from January 2019 to January 2022 were selected as the observation objects and divided into the reference group and the observation group by random drawing method,with forty-three cases in each group.The reference group was treated with trimetazidine,and the observation group was treated with atorvastatin on the basis of control group.Blood lipid indexes[total cholesterol(TC),triglyceride(TG),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C)],cardiac function indexes,incidence of adverse reactions and therapeutic effect were compared between the two groups.Results:Before treatment,there was no significant difference in the levels of TC,TG,HDL-C and LDL-C between the two groups(P>0.05);after treatment,the levels of TC,TG and LDL-C in the two groups were lower than before treatment,and the level of HDL-C was higher than before treatment,he levels of TC,TG and LDL-C in the observation group were lower than that in the control group,and the level of HDL-C was higher than that in the control group,the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in left ventricular posterior wall end-systolic thickness,ventricular septal thickness,left ventricular ejection fraction,end-diastolic diameter and end-systolic diameter of left ventricle between two groups(P>0.05);after treatment,the left ventricular posterior wall end-systolic thickness,ventricular septal thickness,left ventricular end-diastolic diameter and left ventricular end-systolic diameter in both groups were lower than before treatment,and left ventricular ejection fraction was higher than before treatment,the observation group was superior to the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in observation group was lower than that in control group,and the difference was statistically significant(P=0.0259).The total effective rate of observation group was higher than that of control group,and the difference was statistically significant(P=0.0486).Conclusion:The application of atorvastatin combined with trimetazidine in the treatment of coronary heart disease can improve the blood lipid level of patients,promote the recovery of cardiac function,reduce adverse reactions,and the effect is remarkable.